Canagliflozin, a drug approved to lower glucose levels in diabetic patients, can slow the progression of kidney disease, according to a study co-authored by a Stanford Medicine researcher.

Stanford scientists and their collaborators have devised an algorithm to predict the risk of a disease that, untreated, can lead to heart attack or stroke.

On Dec. 14, 2014, after many months of not getting expected results, biochemist Jim Spudich got into bed, read a chunk of a novel, fell asleep and had a dream that would change the thinking in his field about what causes a common and often lethal heart defect.

Stanford researchers presented preliminary findings from a virtual study that enrolled more than 400,000 participants.

Stanford researchers have found a way to predict who will suffer heart problems from a common breast-cancer drug, as well as identified an FDA-approved medication that could mitigate those side effects.

Even a relatively simple heart defect makes a patient much more likely to develop cardiovascular disease as an adult, Stanford researchers say.

With no blood flow to his right lung, infant Carter Johnson was diagnosed with a rare condition called absent right pulmonary artery. His parents turned to Stanford Children’s Health for help.

Patients who took statins less than 70 percent of the time had a 20 percent increase in mortality compared with those taking them at least 90 percent of the time, a Stanford study found.

In preliminary tests, SAMβA (pronounced “samba”) appears to improve heart functions in rats with heart failure caused by a heart attack.

Stanford scientists have discovered a molecule that promotes the growth of collateral arteries in mice. The finding could open the door to developing therapies that help heal heart tissues damaged by disease or heart attack in humans.